RxDoctor Payments Data

Anabela Simon-Lee, MD

Cardiovascular Disease · Birmingham, ALNPI 1063444503

Payments from drug & device makers

$1,121in general payments, 2019–2025

Across 70 payments — averaging $16.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$225
  • Johnson & Johnson$209
  • Merck$129
  • Irhythm Technologies, Inc.$102
  • AstraZeneca$87
  • Preventice Services, LLC$69
  • plus $301 from 15 others

What the payments were for

  • Food & beverage$1,121100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,121 in reported general payments places this provider in the 30th percentile of 292 cardiovascular disease providers in Alabama.

See all cardiovascular disease providers in Alabama

Medicare billing

Part B allowed, 2024
$54,409
Medicare patients
204
Services billed
678

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban253$216,487
EntrestoSacubitril/Valsartan48$56,900
XareltoRivaroxaban39$28,587
Repatha SureclickEvolocumab16$11,734
Icosapent Ethyl15$7,553
Atorvastatin Calcium187$3,198
Losartan Potassium180$3,037
Carvedilol221$2,762
Metoprolol Succinate135$2,302
Ranolazine ErRanolazine21$2,289
Pravastatin Sodium90$1,981
Hydralazine Hcl114$1,837
Flecainide Acetate12$1,636
Pindolol17$1,627
Amlodipine Besylate245$1,561

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$35$216,487253 claims
NovartisEntresto$225$56,90048 claims
Johnson & JohnsonXarelto$209$28,58739 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 292 cardiovascular disease providers in Alabama.

Other cardiovascular disease in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →